United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 1 minute read Pharma Industry News Poxel wraps up enrollment in DESTINY-1 phase 2 trial for PXL065 in NASH Poxel, a French biopharma company, has wrapped up patient enrollment for the phase 2 DESTINY-1 clinical trial, which… bySrinathOctober 9, 2021